Penserra Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 13.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,300 shares of the medical research company’s stock after buying an additional 150 shares during the quarter. Penserra Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $226,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. BB&T Securities LLC grew its stake in Thermo Fisher Scientific by 4.4% during the 1st quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock worth $13,798,000 after buying an additional 3,819 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in Thermo Fisher Scientific by 0.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock worth $101,317,000 after buying an additional 5,213 shares during the period. Mitchell Capital Management Co. increased its position in Thermo Fisher Scientific by 40.3% during the second quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock worth $7,841,000 after buying an additional 12,910 shares during the period. Toronto Dominion Bank increased its position in Thermo Fisher Scientific by 53.5% during the first quarter. Toronto Dominion Bank now owns 107,099 shares of the medical research company’s stock worth $16,450,000 after buying an additional 37,307 shares during the period. Finally, IBM Retirement Fund increased its position in Thermo Fisher Scientific by 117.7% during the second quarter. IBM Retirement Fund now owns 9,537 shares of the medical research company’s stock worth $1,860,000 after buying an additional 5,157 shares during the period. Institutional investors and hedge funds own 83.36% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (NYSE TMO) opened at 191.54 on Tuesday. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $194.30. The company has a 50-day moving average of $184.55 and a 200-day moving average of $173.10. The firm has a market cap of $74.72 billion, a P/E ratio of 33.37 and a beta of 1.05.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. During the same period last year, the business posted $2.03 earnings per share. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. Equities analysts forecast that Thermo Fisher Scientific Inc will post $9.34 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be given a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.

WARNING: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/03/thermo-fisher-scientific-inc-tmo-stake-increased-by-penserra-capital-management-llc.html.

In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 11,318 shares of the business’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the completion of the transaction, the director now directly owns 38,757 shares of the company’s stock, valued at approximately $6,702,635.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Peter E. Hornstra sold 3,894 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total transaction of $721,090.92. Following the transaction, the vice president now directly owns 19,751 shares of the company’s stock, valued at $3,657,490.18. The disclosure for this sale can be found here. Insiders have sold 52,738 shares of company stock valued at $9,302,112 in the last 90 days. Insiders own 0.49% of the company’s stock.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price objective for the company in a report on Thursday, September 7th. Morgan Stanley reaffirmed an “overweight” rating and issued a $220.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. Cowen and Company reaffirmed a “buy” rating and issued a $200.00 target price on shares of Thermo Fisher Scientific in a report on Friday, September 1st. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Finally, Bank of America Corporation reiterated a “buy” rating and set a $210.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $202.21.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.